PPAR alpha + placebo

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyslipidemia

Conditions

Dyslipidemia

Trial Timeline

Jul 1, 2005 → Oct 1, 2006

About PPAR alpha + placebo

PPAR alpha + placebo is a phase 2 stage product being developed by Eli Lilly for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00116519. Target conditions include Dyslipidemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00116519Phase 2Completed